A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HSK47388 in Healthy Volunteers
Latest Information Update: 21 Apr 2025
At a glance
- Drugs HSK 47388 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 21 Apr 2025 New trial record